News
Federal Court Ruling in FTC v. AbbVie
- Details
- Written by FTC Chairman Joe Simons FTC Chairman Joe Simons
- Published: 02 July 2018 02 July 2018
Philadelphia, Pennsylvania - Federal Trade Commission Chairman Joe Simons issued the following statement regarding the decision by the U.S. District Court for the Eastern District of Pennsylvania in the case FTC v. AbbVie. The court ruled that AbbVie used sham litigation to illegally maintain its monopoly over the testosterone replacement drug Androgel, and ordered $448 million in monetary relief to consumers who were overcharged for Androgel as a result of AbbVie’s conduct. This court order represents the largest monetary award ever in a litigated FTC antitrust case.
Promoting Economic Freedom
- Details
- Written by YNN YNN
- Published: 01 July 2018 01 July 2018
Phoenix, Arizona - Arizona has made it a priority to eliminate burdensome rules that hamper innovation. It’s this priority that has created an environment for Arizona businesses and entrepreneurs to develop, innovate, grow and expand.
Quality Inn parking lot Homicide
- Details
- Written by YPD YPD
- Published: 01 July 2018 01 July 2018
Yuma, Arizona - On Saturday, at approximately 5:01a.m., Officers from the Yuma Police Department responded to the 1600 block of Riley Avenue, in reference to a shots fired call.
Grow Economy Grow
- Details
- Written by Yuma News Now Yuma News Now
- Published: 01 July 2018 01 July 2018
Phoenix, Arizona - With over 20,000 farms and ranches in Arizona, the agriculture industry plays a vital role in our state’s economy. The state’s agriculture industry has an economic impact of $23.3 billion and supports over 138,000 jobs in Arizona (2014).
Efforts relating to compounded drugs for patients who cannot use an FDA-approved drug
- Details
- Written by DA Commissioner Scott Gottlieb, M.D. DA Commissioner Scott Gottlieb, M.D.
- Published: 01 July 2018 01 July 2018
Washington, DC - As a physician, I understand how important it can be for health care providers to treat patients with compounded drugs when a patient’s needs cannot be met by FDA-approved drugs. But because compounded drugs are not FDA-approved, it’s important for patients and the medical community to have access to information about the quality of these products. I’m also committed to developing policies and conducting oversight in a manner that seeks to promote use of FDA-approved drugs and minimize the risks to patients who are prescribed a compounded drug.